投融资数据库
免费查数据
注册送3天会员
首页>投融资
Memo Therapeutics
C轮
Memo Therapeutics, a spin-off from ETH Zurich, is focused on developing complete antibodyomes, MemoMAB using its innovative antibody technologies for the treatment of immune related disorders.In February 2022, Memo Therapeutics AG closed an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank.In November 2020, Memo Therapeutic raised CHF 14 million (US $15.8319 million) in Series B financing
基本信息
-
公司全称Memo Therapeutics AG
-
类型抗体发现和免疫库分析平台提供商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址Wagistrasse 27 SCHLIEREN ZUERICH 8952; CH; Telephone: +41445159140;
-
联系电话+41 44515 91 40
-
邮箱info@memo-therapeutics.com
-
成立时间2012-01-01
投融资
-
2024-05-07
-
2024-05-07
-
2023-11-02
-
2023-11-02
-
2022-02-16
-
2022-02-16
-
2021-12-13
-
2021-12-13
-
2020-11-06
-
2020-11-06
-
2018-05-09
-
2018-05-09
-
2015-07-22
-
2015-07-22
- 加载更多
相关投融资企业
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
收并购
Kronos Bio, Inc.于2017年6月2日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，致力于发现和开发新的癌症疗法，旨在通过针对失调转录的精确药物策略来改变患者的预后。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息